Mānuka & Kānuka industry and research Hui

In recent months I’ve been fortunate to attend two Hui (gatherings), involving researchers, industry and iwi representatives, focussed on two important native plants here in Aotearoa New Zealand, Mānuka (Leptospermum scoparium) & Kānuka (Kunzea ericoides).

Mānuka Hui

In June a two day Bioeconomy Science Institute (BSI) Maiangi Taiao Mānuka Hui attended by around 50 people was held at the Plant and Food (now Bioscience Research Institute) premises in Palmerston North. This was an inspiring event which brought together representatives of Māori groups and industry, with researchers from across all four of the previous Crown Research Institutes (CRI’s) and Callaghan Innovation, now combined into the new Bioeconomy Science Institute (BSI, or Maiangi Taiao. A handful of us had also taken part also in two previous hui on ‘Manuka and More’, held in 2016 in Ruatoria and Te Araroa on the east coast of New Zealand’s north island (Tairawhiti), which I wrote about at the time(1). 

Over the two day meeting, there were around 20 short presentations by researchers, industry and iwi representatives on some of the work done in recent years, involving our treasured native plant, Leptospermum scoparium (Mānuka).  It’s impossible to adequately summarise these presentations here, but quite a range of research projects have taken place or started within the past nine years. Much of this involves Mānuka Honey, given how important this industry  is now to many regions of Aotearoa, and how it was the first to put Mānuka on the global map(2).

Kānuka and Mānuka are the dominant native woody species forming early-successional vegetation on formerly forested sites in lowland New Zealand. Their importance as pioneer species has been shown by studies showing that species richness or subsequent biodiversity, was much better in areas where Kānuka and Mānuka were the initial prevalent species(3). A collaboration between Comvita and scientists from the Bioeconomy Science Institute has also demonstrated that planting Mānuka forests on former high-country marginal grazing land can significantly restore biodiversity in as little as five years(4).

The Mānuka honey industry went through a lengthy period of rapid growth in demand and hive numbers over several years prior to 2019. This became unsustainable however, and a range of factors lead to challenging times since then, with registered hive numbers falling sharply from a peak of 918,000 in 2019 to less than 490,000 in 2026. When I wrote about the 2016 Hui, hive numbers were around 350,000(1).

A great deal of evidence however, now suggests much rosier times lie ahead for the Mānuka honey industry. I’ve researched and written four review articles on the science behind this honey over the past 20 months, and the sheer volume and diversity of compelling research findings supporting its many health promoting and medicinal applications, is very encouraging(2, 5, 6, 7).

Jackie Evans and John Oliver from Comvita discussed work their company has been doing on the compound lepteridine, found only in Mānuka honey, recently shown to inhibit enzymes involved in gastrointestinal inflammation(8). A clinical trial involving lepteridine-standardized mānuka honey for the treatment of functional dyspepsia, is currently underway(9).

My talk was entitled “Mānuka – from Plant to Product”, and I spoke about my experience since 1998 with formulating and developing various herbal medicines for internal and topical use containing Mānuka honey, Mānuka oil, dried foliage, and hydroethanolic extracts. In this I incorporated some key issues to consider, when wanting to successfully develop and commercialise health products made using native plants.

Many other interesting presentations were made, including ongoing work into characterising the different genotypes within Mānuka, and methods to ensure better authenticity of Mānuka honey, and to distinguish it from Australian Leptospermum species. The need to preserve and protect mātauranga Māori (traditional Māori knowledge) and taonga species such as Mānuka through placing high value on the interweaving of relationships between people, places and the environment, was also a prominent theme throughout the hui.

A presentation by Grant Smith from the BSI was rather sobering though, as he discussed the continued advance of myrtle rust as a devastating pathogen on several of our other native Myrtaceae species such as ramarama and swamp maire. While others such as Mānuka, Kānuka, Pōhutukawa and rātā have yet to be seriously impacted, the damage this pathogenic fungus has caused to many native bush stands in parts of Australia, and increasing influence of extreme weather events and global warming, suggests a growing threat also to some of our iconic indigenous species(10). The work being done here on identifying mechanisms and genes associated with resistant varieties, may also help our Australian neighbours to better manage their own myrtle rust outbreaks.

At the start of the hui, David Chagne, Jenny Green and Nico Bordes gave an overview of the newly established BSI. Bringing the former CRI’s together again into a combined entity as the primary government agency involved in scientific and industrial research aimed at supporting the growth and resilience of the bioeconomy of New Zealand, makes absolute sense in my view.

Launch of the Bioeconomy Science Institute

Establishment and development of the Biodiscovery Platform, a $42 million government investment to support the development of high-value products and innovation over the next 7 years, was also discussed. This identified the shared sectors direction to build impactful fundable pathways, incorporating a fit for purpose, Treaty-based approach(11). The Biodiscovery Platform is in the process of setting priorities and exploring possible research partnerships. A key objective as a sector enabler is to invest in activities that bring groups together, and to establish clear, repeatable pathways for research into our native plants and their bioactivities and possible commercialisation pathways.

Kānuka Hui

A couple of months later in August, an inaugural hui dedicated to Kānuka (Kunzea ericoides), another highly endemic native species to Aotearoa, was put on by the Kānuka Charitable Trust (KCT), with support from the BSI. The Kānuka Charitable Trust was established in 2023 by a group of Māori landowners and business leaders to protect Kānuka as a taonga species and ensure Māori values guide the development of an emerging Kānuka industry, with Manu Caddie and Richard Manning as founding directors(12).

The hui was facilitated mostly by Nikki Harcourt and Manu Caddie, and attended by landowners, growers, essential oil producers, scientists and researchers and a range of people working with kanuka in their various companies and industries. While as with Mānuka these have to date been based almost entirely on essential oil and honey production, potential applications for other types of products or uses of this botanically related native tree, were discussed.

While ten years ago very little attention was given to Kānuka, it is an important species in forest regeneration. It has been widely planted on erosion-prone land, supports carbon sequestration, encourages biodiversity in flora and fauna, and contributes to rural employment.

Like its botanically related cousin Mānuka, it also possesses many medicinal properties. Traditional applications include for wounds and inflammatory skin conditions, and for several conditions affecting the digestive tract(13). 

Research within the last few years has shown antibacterial and antifungal activities for Kānuka oil against a range of organisms, including Propionibacterium acnes, and MRSA(14).  Its chemistry and relative bioactivities are variable depending on the location, season and extraction methods, but α-pinene is generally the most abundant compound.

Favourable results were reported from a 2022 clinical trial involving application of a 3% kānuka oil cream for eczema, funded by Hikurangi Bioactives, Honeylab and Callaghan Innovation(15). However, challenges have been encountered with commercialising this product in export markets, including unanticipated regulatory barriers in relation to being able to make therapeutic claims.

Authenticity work

Given some of the mistakes made by the Mānuka honey industry in the past, efforts to establish product authenticity are vital for the future Kānuka industry, in order to ensure product is true to label and to protect its market value and supplier reputation.

Much good work has been done and is underway in this area, particularly that by Nigel Perry from Plant & Food Research, on the phytochemistry and potential markers in Kānuka oil(16). David Speed from ALS Analytica, summarised ongoing studies into identification and characterisation of novel constituents of Kānuka, and distinguishing this from Australian Kunzea species. The monoterpene compound α-pinene is generally most prevalent in Kānuka oil, rather than the β-triketones characteristic of good quality Mānuka oil.

A talk by Sri Govindaraju of PAQ Laboratories, which provides specialist testing techniques to support the local honey industry, described how they have developed an assay method for Kānuka honey, and definitions for multifloral or monofloral honey. Currently a lot of blending of different honey suppliers is occurring, with the true volume of Kānuka honey being produced, is not being captured. The last two years had also seen low yields for Kānuka honey supplies, due to heavy rainfall during the short harvest season.

Kānuka honey was found to contain relatively high amounts of type-2 arabinogalactan proteins, which may contribute to immunostimulant and immunomodulatory properties(17).

Being able to further utilise natural waste products or normally discarded plant parts after harvest or extraction of their most desirable components, and fostering a more sustainable and circular economy, makes absolute sense in the world we live in today.  During extraction of the essential oil of Kānuka, large volumes of hydrosols, or aqueous preparations infused with mostly water soluble plant compounds, are produced. These also have many potential applications in human and animal health. Christel Brunschwig from the BSI discussed research into valorising the spent brush not only into hydrosols, but also as a potential biofuel source or feedstock for other types of processing or production operations.

Karl Fraser and Melissa Savage discussed work they are doing on environmental influences on Kānuka oil production, and an ecologist Meg Gray summarised the impact of cyclones, goats and deer grazing, and water quality, on the quality of a Kānuka forest. Pest control is now recognised as being crucial to avoid forest stagnation and loss of biodiversity, as well as the ability of a Kānuka forest to capture carbon.

Lessons learnt

I spoke about some of the lessons learnt from the Mānuka industry to date, and from my previous NHP industry experiences, including the hurdles and steps required to obtain product licences in Australia, and the importance of having a product development and commercialisation strategy that was fit for purpose. My talk also mentioned the importance of understanding regulatory requirements, as all too often these are not well considered, prior to investment in research and product commercialisation.

Another key message we heard at the hui, was that while stories concerning Kaupapa Māori and traditional knowledge are compelling and can support a global marketing strategy for products made from native plants, these need to be supported by collectivism, and consistency. Given the struggle that native plant based industries and companies in Aotearoa have had to date with attaining good and ongoing growth, yet beckoning and growing market opportunities in many overseas markets, this warrants much more consideration by some elements within the broader sector. In order to succeed with the sustainable, ethical and quality based commercialisation of natural health products manufactured using these indigenous plants, it is critical that producers of Mānuka and Kānuka work collectively to develop and support industry standards, certification, and consistent and adequately resourced research and marketing efforts.

References:

  1. Rasmussen PL. Mānuka and More. www.herbblurb.com November 18, 2016.
  2. Rasmussen PL. Mānuka and other Honeys – exciting recent research. www.herbblurb.com November 30, 2024.
  3. Sullivan Jon J, Williams Peter A, Timmins SM. (2007) Secondary forest succession differs through naturalised gorse and native kānuka near Wellington and Nelson. New Zealand Journal of Ecology 31(1): 22 – 38©New Zealand Ecological Society.
  4. https://www.bioeconomyscience.co.nz/news-and-events/news/2026-news/biodiversity-benefits-of-large-scale-manuka-forest-planting
  5. Rasmussen PL, Manuka honey as a medicine. New Zealand Doctor, 15 February 2025. ISSN
  6. Rasmussen PL. Honey as a medicine: Special properties of mānuka honey. Pharmacy Today, 1 October 2024, published by The Health Media Ltd, Auckland, ISSN 1170-1927.
  7. Rasmussen PL. Mānuka honey shows promise in cancer prevention and as treatment adjunct. 1 December 2024, published by The Health Media Ltd, Auckland, ISSN 1170-1927.
  8. Lin B, Nair S, Fellner DMJ, Nasef NA et al, The Leptospermum scoparium (Mānuka)-Specific Nectar and Honey Compound 3,6,7-Trimethyllumazine (LepteridineTM) That Inhibits Matrix Metalloproteinase 9 (MMP-9) Activity. Foods. 2023 Nov 9;12(22):4072. 
  9. Ombasa L, Miller J, Ware L, Abbotts-Holmes H et al, Impact of Mānuka Honey on Symptoms and Quality of Life in Individuals With Functional Dyspepsia: Protocol for a Feasibility Randomized Controlled Trial. JMIR Res Protoc. 2025 May 21;14:e66417.
  10. Rasmussen PL. Mānuka and Myrtle Rust. www.herbblurb.com July 19, 2017.
  11. https://www.mbie.govt.nz/about/news/government-launches-biodiscovery-platform-to-grow-new-zealands-bioeconomy.
  12. https://www.hakanuka.co.nz/
  13. Rasmussen PL, Kānuka & Inflammation. Phytomed Medicinal Herbs Ltd, Dec 2022. https://www.phytomed.co.nz/blogs/phytobrief/kanuka-inflammation.
  14. Haira TH, Ooi RJ, Pay RA, Paenga B, Caddie M, Skinner D, Harcourt N, Jackson M, Keyzers RA, Munkacsi AB. Antimicrobial-guided metabolomic analysis of essential oil derived from the Aotearoa New Zealand endemic plant Kunzea robusta (Kānuka). Fitoterapia. 2025 Jul;184:106592.
  15. Shortt N, Martin A, Kerse K, Shortt G et al, Medical Research Institute of New Zealand’s Pharmacy Research Network. Efficacy of a 3% Kānuka oil cream for the treatment of moderate-to-severe eczema: A single blind randomised vehicle-controlled trial. EClinicalMedicine. 2022 Jul 15;51:101561.
  16. Perry N. Kanuka oil: current knowledge and potential markers. Plant & Food Research Dunedin, October 2022

Bird Flu – an increasing risk to animal and human health

by Phil Rasmussen

Aotearoa New Zealand has in the past two weeks detected its first cases of bird flu, a highly contagious strain of the H5N1 influenza A virus, that can spread rapidly in birds(1). This came less than a month after the first case of H5N1 bird flu was detected in Australia.

Waterfowl such as ducks, geese and swans and shorebirds are the natural reservoir of all known influenza A viruses. First detected in poultry in China in 1996, the H5N1 avian influenza virus has evolved into a significant global public health hazard, primarily owing to its high pathogenicity and potential for interspecies transmission. Extensive genetic diversification has occurred since 2005, including the formation of hundreds of genotypes following reassortment with other avian influenza A viruses.  Highly pathogenic H5N1 avian influenza (HPAI) A virus has spread widely through many regions of the world, causing infections of numerous terrestrial, seabird, shorebird, and migratory wild bird species(2). Since 1997, multiple outbreaks of avian influenza in domestic poultry have occurred, and the current 2.3.3.4.4b clade of H5N1 which emerged in 2020, has now become widespread(3, 4).

Migratory birds are the most likely pathway for the virus to come here, as Aotearoa is a seasonal home to several species who migrate from and travel between here and far away places including the Antarctic, other islands in the Pacific, Australia, China, Alaska, Siberia, and northern Asia. The first case was a wild brown skua found on Petone Beach in Lower Hutt.

Efforts to protect some of our already threatened native bird species such as kākāpō, takahē, tūturuatu (shore plover), kakī (black stilt) and kākāriki karaka (orange-fronted parakeet) by vaccination and isolation are underway.  The second bird confirmed to have bird flu here was a native kāhu or swamp harrier hawk, which doesn’t bode well given many of these species are already vulnerable. While vaccination may help save some, it has obvious limitations and only gives around 6 months of protection, therefore additional control measures are urgently needed.

Other biosecurity measures are now being implemented by the Ministry of Primary Industries, Department of Conservation and poultry farmers(5, 6). This includes PSE protection measures, moving chickens indoors, and lockdowns.  As has occurred overseas, it seems likely that New Zealand poultry farms will at some stage become affected by this virus, potentially leading to the deaths of many millions of birds.

Potential transmission to dairy cows

Highly pathogenic H5N1 influenza was first detected in dairy cows in Texas in March 2024. The virus then disseminated rapidly, causing widespread outbreaks in dairy cattle across the United States(7, 8, 9, 10). Over 1000 herds in at least 19 states have been affected to date(11, 12).

Most cattle recovered in two to three weeks with supportive care, but the impact of the virus on dairy cattle varied from nonclinical to severe clinical signs and death. Up to 20% of each herd in the U.S. outbreaks developed clinical disease with symptoms such as reduced milk production, thicker colostrum-like milk, reduced appetite, lethargy, fever and dehydration. This lead to substantial economic losses(9, 12).  

At first, many American dairy producers did not report clinical signs in their cows or test for the virus. Cats and peridomestic birds on many affected farms died from viral exposure. A number of dairy workers showed signs of conjunctivitis, which was confirmed to be due to H5N1(12).

This represents a significant expansion in the mammalian host range of highly pathogenic H5N1.  Genomic analysis and epidemiological investigation suggests a reassortment event in wild bird populations preceded a single wild bird-to-cattle transmission episode. The movement of asymptomatic or presymptomatic cattle also likely played a role in the spread of HPAI within the United States dairy sector(7).

While infectious virus is detected in milk following mammary infection, unpasteurised milk ingestion by calves doesn’t seem to cause overt disease(13). However, the risk to humans from drinking raw (unpasteurised) milk from infected cows remains unknown, and virologists in the US have advised against this.  American authorities have confirmed that pasteurization inactivated the virus in dairy products and showed that it was very rarely detected in beef from affected cows.

Two years later, the U.S. outbreak of the H5N1 influenza virus in cattle appears to be waning, easing fears that it could cause long-lasting damage to the dairy industry or mutate into a human pandemic form. However, it remains a problem in some states, and efforts to eliminate it entirely face formidable challenges.  The mechanisms of transmission within and between dairy herds also remains a critical question that has yet to be fully answered(13, 14). American virologists have advocated strongly for precautions to be taken by dairy or poultry farm workers, and that those with backyard birds, chickens or pigeons, should also be careful. Keeping dogs and cats away from dead birds,  is also recommended(15).

The persistence of the H5N1 virus in U.S. dairy cattle and the fact it has adapted to infect another key mammalian species, coupled with its broad and unprecedented host range, are alarming developments. It also presents a public health threat due to the establishment of distinct transmission chains linking wild birds, cattle, the environment, and humans.

This is highly relevant to our situation here in Aotearoa New Zealand, given that the dairy industry is our largest export earner, and is based largely on outdoor grazing. While the U.S. outbreak has to date been confined to that country, the risk of transmission of bird flu from wild or migratory birds to cattle as occurred in the U.S., appears very real. If highly pathogenic H5N1 become established in dairy cows here, it could have serious biosecurity, public health and economic consequences. Measures to increase surveillance, develop animal vaccines and treatment agents, enhance farm biosecurity, and continue to ensure dairy product safety, should be considered. Incorporation of a medicinal plant programme, could also make a valuable contribution as part of these measures.

Risk to Humans

While primarily affecting avian species, H5N1 has repeatedly breached species barriers, infecting mammals including seals, dolphins, seals, foxes, otters and cattle(16). As with the SARS-1 and SARS-2 (Covid-19) viruses, which originated from viruses in birds and bats, H5N1 also has the potential to infect humans.

The first known human infection with a highly pathogenic H5N1 influenza A virus appeared in China in 1997. Between 2003 and 2017, the WHO documented an additional 862 human cases, mainly from southeast Asia and Egypt, with a mean annual case fatality rate of 56%(17).

Human cases fell after 2016, but H5N1 clade 2.3.4.4b viruses then appeared in Europe and spread rapidly to the Americas. Human infections of this genotype have been relatively rare to date, and until the US dairy outbreak, mostly occurred in those with unprotected exposure to sick birds. Many instances of poultry workers being infected have been reported(18).

Since the start of the USA dairy outbreak, the H5N1 virus spread from dairy cattle to cats, mice, peridomestic birds, species such as skunks and raccoons, as well as humans.  Between March 2024 and May 2025,  70 human cases of highly pathogenic H5N1 were reported in the United States, although it is likely that the true number of cases was considerably more(12). Of these 41 were exposed to dairy cows, 24 to commercial poultry, two to backyard poultry and three had an unidentified source of exposure. All sequenced viruses were clade 2.3.4.4b. Overall, 62 cases (89%) reported eye redness, 32 (46%) fever and 29 (41%) respiratory symptoms; 54 of 67 cases (81%) reported receiving antiviral treatment. Most illnesses were mild; however, four patients were hospitalized. Of the hospitalized patients, three had pneumonia and one died(19).

While evolution of the virus to a strain capable of rapid human-to-human transmission hasn’t occurred as yet, history and science tell us that such a worrying development remains possible.

The 1918-1920 so-called Spanish flu (which actually began in the U.S.), was caused by a highly lethal strain of the H1N1 subtype of the influenza A virus, which likely originated in birds, before adapting in humans. This was an RNA virus that spread incredibly fast worldwide, ultimately infecting an estimated one-third of the global population and causing the deaths of an estimated 20 to 30 million people(20, 21). Despite our understanding of viral transmission and public health measures now being better than they were in 1918, the potential for an epidemic or pandemic is a concern.

Several outbreaks of bird flu have occurred since 2005, when H5N1 in birds was described as “public health enemy number 1”, and likely to lead to a global pandemic. At that time, highly pathogenic H5N1 influenza A viruses were spreading relentlessly across the globe, causing widespread death in poultry, substantial economic loss to farmers, and infections reported in more than 300 people with a very high mortality rate of 60%(22). As it happened, Covid-19 pipped it at the post, but that didn’t mean that the risk of a future H5N1 pandemic went away.

Detection of the D1.1 genotype primarily circulating in wild birds, was reported in dairy cows in early 2025. Unlike the B3.13 virus circulating in cattle, this has been associated with severe disease in humans, and resulted in two deaths(17, 23). The co-circulation of B3.13 and D1.1 viruses in dairy cows increases the risk of reassortment and viral evolution to a more virulent strain. Genotype D1.1 has now also been detected in domestic cats.

However humans have some residual or existing immunity to H5N1 through our long term exposure to other influenza viruses such as H1N1(24).  Studies in ferrets and using human organoids suggest that currently available seasonal influenza vaccines may confer some degree of protection against H5N1. To what extent however, is as yet unknown(24, 25).

It is hard to know how close we are to the H5N1 virus evolving to become much more virulent in humans. However, reassortment in particular, when co-infection with two viruses occurs (such as a dairy farm worker already with influenza, picking up H5N1), presents a possible mechanism of increased virulence developing.

Some useful phytomedicines

Medicinal plants, having being the mainstay of how humans and animals have treated themselves when unwell throughout virtually all of history, deserve much more attention for their potential value in dealing with H5N1.

In 2005, with a previous version of H5N1 circulating in many bird species around the globe and fears mounting of this triggering a human pandemic, I researched the history of infectious viral diseases and what was known about the H5N1 strains at the time(26, 27).

Below is a reproduction of part of an article I wrote on Avian Influenza in November 2005, for a practitioner publication produced by a company I founded and was then managing. While an update is now called for, much of the information provided is still highly relevant to the current H5N1 situation here in Aotearoa New Zealand.

Avian Influenza Update; excerpts from an article by Phil Rasmussen & edited by Noeline Jonkers, in Phytonews 23, published by Phytomed Medicinal Herbs Ltd, November 2005:

Echinacea:

Echinacea has been shown in animal studies to impart protection against mortality from various viruses(28,29), and several clinical trials have shown beneficial effects of Echinacea during the treatment of colds and influenza(30-34).

Increased numbers of circulating white blood cells, monocytes, neutrophils and natural killer (NK) cells, and the phagocytotic abilities of these, are the principle immunological changes associated with Echinacea root usage. These effects are all a reflection of enhancement of the non-specific immune response, whereby the body’s ability to maintain immunosurveillance against a variety of potential viral or bacterial pathogens or spontaneous-developing tumours, is increased.  This aspect of the immune response is quite different to that of the specific immune system as provoked by vaccination, whereby production of specific disease-related antibodies and a subsequent immune response occurs.

Certain of the above effects of Echinacea may at first seem counterproductive during the acute stage of an established H5N1 infection, in which much of the immune system could well be over-activated as described earlier. While activation of innate immune mechanisms such as NK cell activity is useful in the early immune response to most types of influenza(35,36), excessive enhancement of NK cell activity during the acute stage of a H5N1 infection, could perhaps be associated with a theoretical worsening of lung function(37).

At this point however, it is perhaps important to recognise that Echinacea root exhibits pharmacological actions better summarised as being immunomodulatory and anti-inflammatory rather than simply immunostimulant. Its use by experienced practitioners for autoimmune conditions such as asthma and eczema, is also due to its perceived actions as a modulator or regulator of a poorly functioning overall immune system. Additionally, while activation of several inflammatory as well as anti-inflammatory cytokines has been shown for Echinacea both in vitro and in vivo, the specific actions and potencies in this regard vary depending on the type of Echinacea product concerned.

Anti-inflammatory effects of Echinacea root are well established from both its traditional use to treat snake bites and major abscesses, as well as modern pharmacological studies(38-41). Recent studies have also shown that Echinacea alkamides produce a dual modulatory rather than simple stimulant effect on TNF-a expression in humans(42). These and other effects of Echinacea on gene expressions indicate a broad spectrum anti-inflammatory and immunomodulatory response(43), including reduced expression of IL-1β, IL-8 and TNF-α.  Such effects could be helpful during the acute stages of H5N1 infection.

While speculative, modulation of TNF-a and other cytokine expression by Echinacea could therefore be useful in a situation of H5N1 infection during which TNF-α and cytokine production in general, is dysregulated. In addition to these anti-inflammatory and immunomodulatory effects, antioxidant actions by Echinacea could also be helpful during this situation(44).

However, while adequate doses of a good quality Echinacea preparation have been shown to enhance the capability of the body’s immune system to combat existing upper respiratory tract infections, whether such effects would occur to help hasten elimination of a virulent H5N1 infection, remain unknown.

The question also arises as to whether Echinacea is best used as a possible preventative agent to optimise immune defences ready for when an avian influenza pandemic occurs, rather than a treatment when an individual infection has occurred. Optimising immunosurveillance and activity of the non-specific immune system against such a virulent pathogen, while less likely to ensure complete protection than appropriate vaccination, may prevent such a virulent and life-threatening response to its presence.

Other phytomedicines:

Shikimic acid is a phenolic acid compound used as a key starting material in the manufacture of oseltamivir, and found in many plants including Chinese Star Anise (Illicium verum)(45). While this and other shikimic acid rich plants have been increasingly sought after since fears of a pandemic escalated, little evidence exists that shikimic acid itself or plants containing it, could be useful.

American ginseng (Panax quinqefolium) root has a protective effect against winter influenza in institutionalised older adults (see Phytonews 20(46)). More recently, a preventative effect against winter colds has been reported following daily use for 4 months, in a Canadian study involving 323 subjects aged 18-65 years of age(47). A higher immune response from influenza vaccination, has also been produced by concurrent administration of the closely related Panax ginseng(48).

The popular Chinese herb Astragalus membranaceous, traditionally used to help manage viral infections such as the common cold, has also shown some evidence of immune stimulation and antiviral effects(49-51).

Elderflower (Sambucus nigra) is generally used for its diaphoretic and decongestant properties, particularly during hay fever as well as catarrh and fever associated with the common cold or influenza. A clinical trial has found elderberry to have in vitro antiviral effects and reduce the duration and severity of influenza symptoms(52), and possible immunostimulant properties have been reported(53).

The root of Ginger (Zingiber officinale) has immunomodulatory(53) and antiviral properties(55-57), which along with its anti-inflammatory actions, may be useful. The fungus Reishi (Ganoderma lucidum), has established immunomodulatory effects and enhances innate immunity by activating NF-kappaB(58).

Olive leaf (Olea europaea) has become popular over recent years as an alleged treatment for winter influenza, although little published research has appeared until recently(59).

Propolis, the resinous material manufactured by bees from plants and rich in flavonoids, shows in vitro activity against various viruses(60,61), and has proven immunomodulatory and anti-inflammatory effects including down-regulation of inflammatory cytokine production(62,63).

Various plants contain compounds which act as neuraminidase inhibitors in vitro in the same manner as oseltamivir. The best studied of these is 5,7,4”-trihydroxy-8-methoxyflavone(64,65), a flavone closely related to baicalin and baicalein and found in roots of the popular Chinese herb Baical Skullcap (Scutellaria baicalensis), as well as aerial parts of the well-known European Skullcap (Scutellaria lateriflora).

A study just reported using a Chinese formula containing a large amount of baicalin in a pre-clinical animal model of endotoxin-induced lung injury, found a marked reduction in elevated plasma levels and the expressions of several inflammatory cytokines, in lung tissues. The formulation itself (San-Huang-Xie-Xin-Tang), as well as baicalin alone, also reduced plasma concentrations of IL-1b, TNF-α, and expressions of other cytokines associated with lung injury and lethality(66).

This study as well as another finding in vitro antiviral activity against SARS coronavirus for baicalin(66), provides strong support for a potential role for baicalin-containing phytomedicines  in the treatment of acute H5N1 infection. The well-established anti-inflammatory, antioxidant and antimicrobial activities of Baical Skullcap(68), would seem to make further research on this phytomedicine in particular, highly justified.

Other neuraminidase inhibitors include resveratrol (found in red grapes) and emodin derivatives, anthraquinone compounds found in Aloe vera and a number of other laxative phytomedicines(69). The strong laxative effects of these would probably be major limitations to their clinical usefulness at this stage. As for all such compounds, considerations of bioavailability and dosage of each of these herbal medicines that would be required for significant activities need to be made.

With excessive inflammation in the lungs being increasingly related to the virulence of  H5N1, treatment of infected patients with anti-inflammatory drugs or herbal medicines may in some cases be useful. However while the use of corticosteroids together with antiviral medication has been reported to confer clinical benefits in some cases of SARS(70), clinical trials are lacking and such steroid therapy has been linked with residual lung damage following treatment. There nevertheless remains a theoretical potential role for anti-inflammatory phytomedicines or phytochemicals such as curcumin, a key constituent of the cheap spice Turmeric, which is a significant inhibitor of TNF and could help reduce the adverse effects of excessive cytokine release.

While in all cases it is at this stage conjectural as to whether these or other various natural treatments would be helpful during an H5N1 pandemic, the seriousness of the situation now arising warrants a systematic evaluation of these and other herbal medicines as possible alternative or adjunctive treatments to anti-viral drug or vaccine therapy. 

July 2026 Update:

Significantly, each of the aforementioned herbs as well as the propolis made by bees using plant phytochemicals, are already being grown or can easily be grown here in Aotearoa and their production scaled up rapidly, provided the required commitment and funding support to do so, is provided.

One of these, Scutellaria baicalensis (Baical Skullcap) is a widely used medicinal plant in Asia, and one of the species that I am participating in growing trials with, involving a landowner group here in Aotearoa New Zealand. I recommended this species for the trials based upon the huge amount of scientific evidence for its effectiveness in many human health conditions, my clinical experience with using it in hundreds of patients, its growing global demand, our need to strengthen our medicine security and diversify our rural economies, and a view it would grow very well in our country.  Early results from these trials have been promising.

As I summarised in blogs in April and October last year, Baical skullcap has recently been shown to possess potential applications for animal health in addition to its well-established benefits to treat human illnesses including infectious and neurological diseases, inflammatory and allergic conditions and cancer(71, 72). A study published last year by Chinese researchers also found an extract of the stems and leaves of Baical skullcap to offer promise in helping farmers to manage respiratory tract pathogens in laying hens.(73)

Supplementation of chickens vaccinated against the H5N1 avian influenza virus with oral extracts from Astragalus and Ginseng (two other species which are being trialed or cultivated here in Aotearoa), has been shown to increase their antibody production and immune response. This suggests their potential also as adjunctive treatments, to protect chickens against this virus(74).  Researchers in Thailand recently screened some Asian medicinal plant extracts and found ethanolic extracts of turmeric root as well as the leaf of guava (Psidium guajava), to have good in vitro activity against the H5N1 influenza virus(75).

A call to Action

Highly pathogenic avian influenza (HPAI) H5N1 continues to pose a serious threat to global health due to its increasing geographic spread, expanding host range including recent mammalian infections, and relatively high mortality in human cases.

The potentially devastating impact of this highly pathogenic H5N1 virus on our native birds as well as poultry industry, and risk of spread to the dairy industry, calls for urgent steps from the government and industry sectors and stakeholders.  The propensity of this strain of H5N1 to mutate, and potentially into a form more easily transmissible between humans, is a reason for concern. To effectively manage highly pathogenic avian influenza, a comprehensive, collaborative and forward thinking programme that invokes the principals of a One Health perspective involving all stakeholders, is recommended.

Despite the availability of vaccines and antivirals for seasonal influenza, effective prophylactic and treatment options for H5N1 remain limited.  Several drugs show promise in preclinical studies, but clinical data specifically for H5N1 is lacking.

Fortunately, compelling research suggests that several medicinal plants could make a valuable contribution as part of these management efforts, many of which we can easily grow here. Incorporating some of these into longer term farm management practices would also have other sustained benefits for our important animal based agricultural economy, as well as our resilience as a food producing nation, and protection of our rich native species biodiversity.

References:

  1. First case of bird flu confirmed in New Zealand. New Zealand Herald, 15 July 2026.
  2. Shi J, Zeng X, Cui P, Yan C, Chen H. Alarming situation of emerging H5 and H7 avian influenza and effective control strategies. Emerg Microbes Infect. 2023 Dec;12(1):2155072. 
  3. Krammer F, Hermann E, Rasmussen AL. Highly pathogenic avian influenza H5N1: history, current situation, and outlook. J Virol. 2025 Apr 15;99(4):e0220924. 
  4. Centers for Disease Control and Prevention. Technical report: June 2024 highly pathogenic avian influenza A (H5N1) viruses. https://www.cdc.gov/bird-flu/php/technical-report/h5n1-06052024.html.
  5. https://www.mpi.govt.nz/biosecurity-in-nz/dont-let-bird-flu-take-flight?utm_source=google&utm_medium=paidsearch&utm_campaign=High+Pathogenicity+Avian+Influenza+H5N1+2025-26&gad_source=1
  6. https://birdflu.pianz.org.nz/
  7. Nguyen TQ, Hutter CR, Markin A, Thomas M et al, Emergence and interstate spread of highly pathogenic avian influenza A(H5N1) in dairy cattle in the United States. Science. 2025 Apr 25;388(6745):eadq0900.
  8. Caserta LC, Frye EA, Butt SL, Laverack M et al. Spillover of highly pathogenic avian influenza H5N1 virus to dairy cattle. Nature. 2024 Oct;634(8034):669-676. doi: 10.1038/s41586-024-07849-4. 
  9. Peña-Mosca F, Frye EA, MacLachlan MJ, Rebelo AR et al, The impact of highly pathogenic avian influenza H5N1 virus infection on dairy cows. Nat Commun. 2025 Jul 15;16(1):6520.
  10. Lewis N, Beer M. Stop H5N1 influenza in US cattle now. Science. 2024 Jul 12;385(6705):123. doi: 10.1126/science.adr5866. Epub 2024 Jul 11. PMID: 38991057.
  11. https://www.cdc.gov/bird-flu/situation-summary/mammals.html
  12. Lombard J, Stenkamp-Strahm C, McCluskey B, Abdul-Hamid C, Cardona C, Petersen B, Russo K. Invited review: The One Health challenges and opportunities of the H5N1 outbreak in dairy cattle in the United States. J Dairy Sci. 2025 Jul;108(7):6513-6537. 
  13. Lee C, Tarbuck NN, Cochran HJ, Foreman BM et al, Dairy cows infected with influenza A(H5N1) reveals low infectious dose and transmission barriers. Nat Commun. 2026 May 24. doi: 10.1038/s41467-026-73490-6.
  14. Ding K, Ding Y. H5N1 avian influenza in dairy cattle: Molecular adaptation, transmission mechanisms, and control strategies. Virology. 2026 Aug;621:110927. 
  15. https://www.avma.org/resources-tools/animal-health-and-welfare/animal-health/avian-influenza/avian-influenza-virus-type-h5n1-us-dairy-cattle
  16. Man W, Du L, Liu Y, Pang Z et al, Evolution of H5N1 Cross-Species Transmission: Adaptive Mutations Driving Avian-to-Human Infection. Adv Genet (Hoboken). 2026 Jan 11;7(1):e00051.
  17. Sykes JE. Companion animals and H5N1 highly pathogenic avian influenza: cause for concern? J Am Vet Med Assoc. 2025 Aug 8;263(11):1355-1363. 
  18. Hatta Y, De La Cruz JA, Murray T, Hiatt B et al, Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Poultry Farm Workers, Washington, USA, 2024. Emerg Infect Dis. 2025 Dec;31(12):2297-2301.
  19. Rolfes MA, Kniss K, Kirby MK, Garg S et al, Human infections with highly pathogenic avian influenza A(H5N1) viruses in the United States from March 2024 to May 2025. Nat Med. 2025 Nov;31(11):3889-3898
  20. Taubenberger JK, Kash JC, Morens DM. The 1918 influenza pandemic: 100 years of questions answered and unanswered. Sci Transl Med. 2019 Jul 24;11(502):eaau5485.
  21. Köntös Z. Lessons should be learned: Why did we not learn from the Spanish flu? SAGE Open Med. 2024 May 29;12:20503121241256820.
  22. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet. 2008 Apr 26;371(9622):1464-75
  23. Mezhenskaia D, Babujee L, Lim A, Guan L, Nguyen D, Gu C, Neumann G, Poulsen K, Eisfeld AJ, Kawaoka Y. Isolation and characterization of a clade 2.3.4.4b genotype D1.1 H5N1 virus from dairy cattle in Wisconsin. J Virol. 2026 Jul 10:e0076126.
  24. Li C, Yu Y, Wan Z, Cai JP et al. Cattle and human organoids reveal 2.3.4.4b H5N1 cross-species transmission potential and neuraminidase-specific neutralizing antibodies in humans. Nat Commun. 2026 Jul 8;17(1):5585. 
  25. Tseng I, Huang YC, Shih WL, Chou CH et al, Cross-protection against highly pathogenic avian influenza H5N1 virus from seasonal influenza vaccines: a systematic review and meta-analysis of ferret studies. Emerg Microbes Infect. 2026 Dec;15(1):2654278.
  26. Rasmussen PL, Person to person transmission of Avian Influenza. Phytonews 21, published by Phytomed Medicinal Herbs Ltd, Auckland, New Zealand, March 2005. ISSN 1175-0251.
  27. Rasmussen PL, Avian Influenza Update. Phytonews 23, published by Phytomed Medicinal Herbs Ltd, Auckland, New Zealand, November 2005. ISSN 1175-0251
  28. Hayashi I et al, Nihon Rinsho Meneki Gakkai Kaishi.;24(1):10-20. Feb 2001.
  29. Currier NL, Miller SC. J Altern Complement Med 7(3):241-251, Jun 2001.
  30. Giles et al. Pharmacotherapy. 20(6):690-7, 2000.
  31. Melchart et al. Cochrane Database Syst Rev. (2):CD000530, 2000.
  32. Percival SS. Biochem Pharmacol. 60(2):155-8, 2000.
  33. Hoheisel O. et al,  Eur. J. Clinical Research, 9, 261-268, 1997.
  34. Barnes J et al, J Pharm Pharmacol 57(8):929-954, Aug 2005.
  35. He XS et al. J Clin Invest.;114(12):1812-9. Dec 2004.
  36. Liu B et al, J Gen Virol 85(Pt 2):423-8, Feb 2004.
  37. Wei H  et al, J Allergy Clin Immunol. 115(4):841-7. Apr 2005.
  38. Tragni E. et al, Pharmacol Res Comm, 20(5), 87-90, 1988.
  39. Muller-Jakic, B. et al, Planta Med 60(1), 37-40, 1994.
  40. Clifford et al. Phytomedicine. 9(3):249-53,  2002.
  41. Rasmussen P Phytonews 14 12, Phytomed Medicinal Herbs Ltd, Auckland, New Zealand. ISSN 1175-0251, December 2002.
  42. Gertsch J et al, FEBS Lett 577, 563-569, 2004.
  43. Randolph RK et al, Exp Biol Med (Maywood).;228(9):1051-6. Oct 2003.
  44. Goel V et al, Phytother Res 19. 689-694, 2005.
  45. Lee SW et al, Planta Med 69(9):861-864, Sept 2003.
  46. Rasmussen P Phytonews 20 4, Phytomed Medicinal Herbs Ltd, Auckland, New Zealand. ISSN 1175-0251, December 2004.
  47. Predy GN 2005 CMAJ. 25;173(9):1043-8. Oct 2005.
  48. Scaglione F et al, Drugs Exp Clin Res 22(2):65-72, 1996.
  49. Block KI, Mead MN. Integr Cancer Ther 2(3):247-267, Sept 2003.
  50. Yesilada E et al, J Ethnopharmacol. 4;96(1-2):71-7. Jan 2005
  51. Guo FC et al. Poult Sci. 83(7):1124-32. Jul 2004
  52. Zakay-Rones Z et al, J Altern Complement Med 1(4):361-369, 1995.
  53. Barak V et al, Isr Med Assoc J 4(11 Suppl):919-922, Nov 2002.
  54. Sohni Y et al, J Ethnopharmacol 54(2-3):119, 1996.
  55. Denyer CV et al, J Nat Prod 57(5):658-662, May 1994.
  56. Dugenci SK et al, J Ethnopharmacol  88(1):99-106. Sep 2003
  57. Chrubasik S et al, Phytomedicine 12(9):684-701. Review. Sep 2005
  58. Kuo MC J Ethnopharmacol. 14; Sep 2005
  59. Micol V et al. Antiviral Res.66(2-3):129-36. Jun. 2005
  60. Adb El Hady FK, Hegazi AG. Z Naturforsch 57(3-4):386-394, Mar-Apr 2002.
  61. GekkerG et al. Ethnopharmacol 87(1):93-97, Jul 2003.
  62. Ansorge S et al, Z Naturforsch 58(7-8):580-589, Jul-Aug 2003.
  63. Sa-Nunes A et al, J Ethnopharmacol 87(1):93-97, Jul 2003.
  64. Nagai T et al, Chem Pharm Bull 38(5):1329-1332, May 1990.
  65. Nagai T et al, Antiviral Res 26(1):11-25, Jan 1995.
  66. Lo YC et al, J Ethnopharmacol 101(1-3):68-74, Oct 3, 2005.
  67. Chen F et al, J Clin Virol 31(1):69-75, Sept 2004.
  68. Chuang HN et al, Planta Med 71(5):440-445, May 2005.
  69. Lee CH et al, Arch Pharm Res 26(5):367-374, May 2003.
  70. Wang C-H et al, Resp Res 6:42, 2005.
  71. Rasmussen PL, Baical Skullcap – useful for anxiety, neurological & mood disorders. www.herbblurb.com Oct 17, 2005.
  72. Rasmussen PL, Baical Skullcap – additional uses for aerial parts. www.herbblurb.com Apr 7,  2005.
  73. Wang X, Wu S, Guo N, Yu F et al, Scutellaria baicalensis stem and leaf combat chicken-derived respiratory bacterial infection. Microb Pathog. 2025 May;202:107439. 
  74. Abdullahi AY, Kallon S, Yu X, Zhang Y, Li G. Vaccination with Astragalus and Ginseng Polysaccharides Improves Immune Response of Chickens against H5N1 Avian Influenza Virus. Biomed Res Int. 2016;2016:1510264.
  75. Sornpet B, Potha T, Tragoolpua Y, Pringproa K. Antiviral activity of five Asian medicinal pant crude extracts against highly pathogenic H5N1 avian influenza virus. Asian Pac J Trop Med. 2017 Sep;10(9):871-876.

Baical Skullcap – additional uses for aerial parts

Baical Skullcap

Scutellaria baicalensis (known as Baical skullcap or Huangqin) is an important plant medicine in China, Russia, Mongolia, Korea and Japan.  It is a prominent constituent in a large number of Traditional Chinese Medicine formulations used to treat numerous disease conditions. These include allergic diseases, respiratory tract infections, pneumonia, colitis, hepatitis, dementia, Parkinson’s disease and cancer.

Scutellaria baicalensis is botanically related to Scutellaria lateriflora (commonly known as Skullcap or American Skullcap in western Herbal Medicine), best known for its anxiolytic and sedative properties.  However, the root of Baical skullcap is the plant part traditionally used, whereas for American Skullcap it is the aerial parts (leaves and stems).

Over 50 compounds have been isolated and identified from Baical skullcap, including flavonoids, terpenoids, volatile oils and polysaccharides. Flavonoids including baicalein and its metabolite baicalin and wogonin, are key active phytochemicals.  These occur in highest levels within the root, and virtually all research on this impressive plant has involved use of root-derived preparations.

Research on aerial parts

While not well known, other parts of Baical skullcap, are also sometimes used for therapeutic purposes.

Improved cognition in vascular dementia and in animal models of Alzheimer’s disease, and prevention of cerebral ischaemia reperfusion injury, have previously been reported in rats following administration of concentrated flavonoid extracts made from stems and leaves of Scutellaria baicalensis (1-5). While required dosages were large, favourable results using these animal models for common age-related conditions are encouraging. They also highlight potential applications in both veterinary and human medicine, for parts of the plant normally regarded as waste products from root farming operations. These have a different phytochemistry to the root, with the flavonoid scutellarin being predominant.

Poultry industry applications

The poultry industry is a huge global operation, but as it has grown and poultry farms become larger, challenges in relation to animal health and husbandry have also increased.

Most chicken farms around the world still rely heavily on regular use of antibiotics for disease prevention and control, and sometimes also to promote growth. However, such widespread use can lead to deposition of antibiotic residues in the soil and waterways, and the promotion of microbial mutations and antibiotic resistance. These are serious consequences for the environment, animal and human health(6).  Since 2006, the European Union has banned the use of antibiotics as growth promoters in farm animals. Their use in Australia and New Zealand, is also now limited to sick animals only.

Bacterial and viral infections nevertheless remain challenging for poultry farmers, and can lead to substantial losses in laying hens or in those farmed for meat.  Despite improvements in housing and management practices in recent years, infections such as salmonella or bird flu remain a constant threat.

A recent study by Chinese researchers, has now found the normally discarded tops of Baical skullcap to offer promise in helping farmers to manage respiratory tract pathogens in poultry.

Recent research

The study, conducted by agricultural researchers and veterinarians in Beijing, investigated the effects of an ethanolic extract of the stems and leaves of Scutellaria baicalensis, on respiratory symptoms in diseased laying hens.

Three groups of 60 diseased laying hens were randomly selected. One group was given a diet supplemented with dried Baical skullcap stem and leaf powder, another with a hydroethanolic extract of the stem and leaf, and one the usual diet only, for a period of 12 days.

After the 12 day supplementation period, hens given the Baical skullcap extract had a marked improvement in respiratory tract symptoms such as coughing, a runny nose and labored breathing. Subsequent biopsies revealed a significant improvement in lung tissue lesions and inflammation. Baical skullcap supplementation was also associated with a significant upward trend in the egg production rate starting 3 days after supplementation commenced, as well as improvements in egg quality(7).

Previous work

Earlier work in Europe found a combination of turmeric and baical skullcap given as a feed additive to chickens decreased gut inflammation and improved the health of chickens with the pathogen Salmonella enteritidis(8). Salmonella is a serious pathogen in chickens which can affect both meat and egg production and quality.

Another recent Chinese study found a combination of baical skullcap with flowers of Lonicera japonica (Japanese honeysuckle, a noxious weed in Aotearoa New Zealand)(9), to mitigate the negative effects of Clostridia perfringens infection in chickens. This is another gastrointestinal pathogen causing reduced growth and mortality in poultry, also normally treated with antibiotics. Mechanisms of action were related to improvement in intestinal barrier function, leading to a positive influence on the growth performance of challenged birds(10).

Economic and environmental benefits

Potential applications to develop animal feed products containing readily available and cheap or free plant materials to manage chicken diseases naturally rather than through agrichemicals, are made apparent by this recent research.

While above ground parts of medicinal plants where the root is harvested are usually returned to the land in the form of mulch or as some form of compost, an ability to utilize these also to produce valuable medicines, is preferential.

The area of commercial cultivation of Baical skullcap in China alone is currently more than four times that of all Aotearoa New Zealand apple and pear orchards combined. This in itself speaks to the market potential of farming for the highly medicinal root.  With additional poultry industry applications being revealed for plant parts generally regarded as a waste byproduct, the case for increased research to further develop a sustainable and profitable scaled up medicinal plant cultivation industry here, continues to strengthen.

Refs:

  1. Cao Y, Liang L, Xu J, Wu J, Yan Y, Lin P, Chen Q, Zheng F, Wang Q, Ren Q, Gou Z, Du Y. The effect of Scutellaria baicalensis stem-leaf flavonoids on spatial learning and memory in chronic cerebral ischemia-induced vascular dementia of rats. Acta Biochim Biophys Sin (Shanghai). 2016 May;48(5):437-46.
  2. Zhao S, Kong W, Zhang S, Chen M, Zheng X, Kong X. Pretreatment with scutellaria baicalensis stem-leaf total flavonoid prevents cerebral ischemia-reperfusion injury. Neural Regen Res. 2013 Dec 5;8(34):3183-92. doi: 10.3969/j.issn.1673-5374.2013.34.002.
  3. Zhang H, Liu QQ, Ding SK, Li H, Shang YZ. Flavonoids From Stems and Leaves of Scutellaria Baicalensis Georgi Improve Composited Aβ-Induced Alzheimer’s Disease Model Rats’ Memory and Neuroplasticity Disorders. Comb Chem High Throughput Screen. 2023;26(8):1519-1532. 
  4. Ma S, Xu CC, Dong YC, Li CX, Shang YZ. Scutellaria Baicalensis Georgi Stem and Leaf Flavonoids Ameliorate the Learning and Memory Impairment in Rats Induced by Okadaic Acid. Comb Chem High Throughput Screen. 2025;28(2):263-277
  5. Wang X, Xie Y, Bayoude A, Zhang B, Yu B. Discovering the Q-marker of scutellaria baicalensis against viral pneumonia integrated chemical profile identification, pharmacokinetic, metabolomics and network pharmacology. J Ethnopharmacol. 2025 Jan 31;340:119232.
  6. Rasmussen PL, ‘Antibiotics and their effects on Plants. www.herbblurb.com July 27, 2017.
  7. Wang X, Wu S, Guo N, Yu F, Xu X, Wang X, Yu X, Liu X, Dong H. Scutellaria baicalensis stem and leaf combat chicken-derived respiratory bacterial infection. Microb Pathog. 2025 May;202:107439. 
  8. Varmuzova K, Matulova ME, Gerzova L, Cejkova D, Gardan-Salmon D, Panhéleux M, Robert F, Sisak F, Havlickova H, Rychlik I. Curcuma and Scutellaria plant extracts protect chickens against inflammation and Salmonella Enteritidis infection. Poult Sci. 2015 Sep;94(9):2049-58.
  9. Rasmussen PL, ‘Honeysuckle and other useful weeds surrounding us. www.herbblurb.com January 24, 2019.
  10. Li S, Zhang K, Bai S, Wang J, Zeng Q, Peng H, Lv H, Mu Y, Xuan Y, Li S, Ding X. Extract of Scutellaria baicalensis and Lonicerae flos improves growth performance, antioxidant capacity, and intestinal barrier of yellow-feather broiler chickens against Clostridium perfringens. Poult Sci. 2024 Jul;103(7):103718.